Enveda

Enveda leverages an AI-driven discovery platform to unlock the hidden chemical potential of nature, enabling drug hunters to work up to four times faster than industry norms. Guided by the belief that the natural world holds vast, unexplored therapeutic wisdom, they aim to accelerate the creation of better medicines for millions.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
Share Price
Series E23 Sep, 2026
***
***
***
Series D4 Sep, 2025
***
***
***
Series C26 Feb, 2025
***
***
***
Series C21 Nov, 2024
***
***
***
Series B14 Jun, 2024
***
***
***
Series B20 Apr, 2023
***
***
***
Series B21 Dec, 2022
***
***
***
Series A22 Jun, 2021
***
***
***
Seed11 Aug, 2020
***
***
***

*** - To view the data, please log into your account or create a new one.

Company valuation calculator

To calculate, specify one of the parameters

News related to Enveda5

Filter by
Sort by
Enveda
Oct 28, 2026 •Show on chart

Enveda Collaborates with Anthropic to Accelerate Drug Development

Enveda is a biotechnology company using AI to translate nature's chemistry into new medicines. Enveda's platform identifies and characterizes molecules produced ...

https://www.streetinsider.com/Business+Wire/Enveda+Collaborates+with+Anthropic+to+Accelerate+Drug+Development/27240969.html
Enveda
Oct 1, 2026 •Show on chart

Enveda Announces Late-Breaker Oral Presentation of New ...

BOULDER, Colo.--(BUSINESS WIRE)-- Enveda, a clinical-stage biotech company developing first-in-class small molecules derived from life's chemistry, ...

https://www.streetinsider.com/dr/news.php?id=27117629
Enveda
Sep 30, 2026 •Show on chart

Enveda Announces Late-Breaker Oral Presentation of New ...

Enveda Announces Late-Breaker Oral Presentation of New Mechanistic and Biomarker Data from the Phase 1b Trial of ENV-294, a Potential First-in-Class Oral ...

https://www.morningstar.com/news/business-wire/20260929731368/enveda-announces-late-breaker-oral-presentation-of-new-mechanistic-and-biomarker-data-from-the-phase-1b-trial-of-env-294-a-potential-first-in-class-oral-therapy-for-moderate-to-severe-atopic-dermatitis-at-the-upcoming-eadv-2026-congress
Enveda
Sep 23, 2026 •Show on chart

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

The idea behind Enveda is that powerful medicines could be harnessed from plants and microbes, ...

https://techcrunch.com/2026/09/23/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-into-clinical-trials/
Enveda
Sep 4, 2025 •Show on chart

Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors

The round was led by Premji Invest with participation from new and existing investors Baillie Gifford, Kinnevik, ...

https://www.businesswire.com/news/home/20250904184822/en/Enveda-Raises-%24150M-Series-D-Funding-to-Reach-Unicorn-Status-Enrolls-First-Patient-in-Lead-Program-and-Adds-Mikael-Dolsten-to-Board-of-Directors

Investors3

Kinnevik ABKinnevik AB
Lux CapitalLux Capital
SanofiSanofi